Clinical trials have found that daily low-dose aspirin can cut the risk of colorectal cancer by roughly half in people with Lynch syndrome (a hereditary condition that sharply raises the likelihood of developing bowel and other cancers), with updated UK health guidelines now recommending the drug as a first-line preventive measure for those affected. A separate three-year trial involving nearly 3,000 colorectal cancer patients found that those who took 160mg of aspirin daily after surgery also saw their risk of cancer recurrence fall by more than half. Researchers say the findings are significant because low doses — between 75 and 160mg — produce far fewer serious side effects than higher doses, making the treatment far more practical for widespread use.